Effect of Oligopin Administration on Ovarian Morphology in Women With Polycystic Ovarian Syndrome (Pcos) Publisher



Sm Sajjadijazi Sayed MAHMOUD ; M Sanginabadi MILAD ; B Moradi BEHNAZ ; Ap Hashemi Taheri Amir PEJMAN ; M Amouei MEHRNAM ; M Qorbani MOSTFA ; S Hosseini SAEED ; M Gity MASOUMEH ; Mr Mohajeritehrani Mohammad REZA ; Sv Taheri Seyed VAHID
Source: International Journal of Clinical Practice Published:2024

Abstract

Background. The effects of oligopin as an antioxidant on polycystic ovarian morphology (PCOM) have not yet been examined. Therefore, the objective of this study was to evaluate the oligopin supplementation on PCOM among patients with polycystic ovarian syndrome (PCOS). Methods. This randomized, placebo-controlled trial was carried out at Shariati Hospital, Arash Hospital, and Yas Hospital, Tehran, Iran, to determine the effect of oligopin (50 mg/d) or placebo in PCOS patients. The ultrasonographic ovarian morphology was assessed in women aged 18-40 years, before and after 3 months of intervention. Results. Among 45 randomized participants, 32 participants, of whom 17 were in the oligopin group and 15 were in the placebo group completed the trial. There was only one adverse event in the oligopin group. The mean (standard deviation) age of the patients was 30.47 (6.30) years and the median (interquartile range) BMI was 27.50 (23.42-33.55). Three months of oligopin therapy significantly decreased ovarian stromal area (p=0.01) and stromal/total area (p=0.003). However, no significant differences were observed in the ovarian volume, ovarian area, 2-9 mm antral follicle counts, or peripheral follicle distribution pattern at 3 months. Conclusion. Among participants with PCOS, the use of oligopin (50 mg) daily, as compared with a placebo, resulted in improvement of the stromal area and stromal/total area at the end of the 3 months of treatment. Further studies are, however, needed to evaluate the longer-term efficacy and safety. This trial is registered with IRCT20140406017139N3. © 2024 Elsevier B.V., All rights reserved.